2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
December 6, 2018BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim AnalysisPrinter Friendly Version
December 4, 2018Data for BeyondSpring’s Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia (CIN) Prevention Shows Differentiated Profile Compared with G-CSF and Adds Additional Protection to G-CSFPrinter Friendly Version
November 27, 2018Plinabulin Newly Granted Patent Covering Method of Use in Prevention of NeutropeniaPrinter Friendly Version
November 8, 2018Clinical Results for BeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Demonstrated Superior Immune Profile Compared to Neulasta®Printer Friendly Version
October 23, 2018BeyondSpring Announces Top Line Positive Efficacy and Safety Data from Phase 2 Study 106 with Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia PreventionPrinter Friendly Version
October 23, 2018BeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Has the Potential to Positively Impact Tumor MicroenvironmentPrinter Friendly Version
October 23, 2018Beyondspring Provides Operational Update and Second-Quarter 2018 Financial ResultsPrinter Friendly Version
October 19, 2018BeyondSpring to Host Second-Quarter 2018 Financial Results and Operational Update Conference Call on October 23, 2018Printer Friendly Version
October 16, 2018BeyondSpring’s Lead Asset, Plinabulin, Prevents Docetaxel Chemo-Induced-Neutropenia (CIN) Due to a Mechanism of Action Differentiated from G-CSFPrinter Friendly Version
October 4, 2018Study Opens of BeyondSpring’s Lead Asset, Plinabulin, and Nivolumab + Ipilimumab in Small-Cell Lung CancerPrinter Friendly Version
October 3, 2018BeyondSpring to Present Clinical Trial Data at Three Upcoming Scientific ConferencesPrinter Friendly Version
September 25, 2018BeyondSpring’s Lead Asset, Plinabulin, Continues to Demonstrate Clinical Superiority Versus Standard of Care for NeutropeniaPrinter Friendly Version
September 19, 2018BeyondSpring Strengthens Intellectual Property Portfolio with Newly Granted U.S. Patent for PlinabulinPrinter Friendly Version
September 6, 2018BeyondSpring’s Lead Asset, Plinabulin, Shows Superior Efficacy Compared to Neulasta for Prevention of Thrombocytopenia Induced by Docetaxel in Phase 2 TrialPrinter Friendly Version
September 4, 2018BeyondSpring to Present at the H.C. Wainwright 20th Annual Global Investment ConferencePrinter Friendly Version
August 15, 2018BeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at IASLC World Conference on Lung CancerPrinter Friendly Version
August 1, 2018BeyondSpring Appoints Richard J. Daly as Chief Operating Officer to Lead the Transition to CommercializationPrinter Friendly Version
June 25, 2018BeyondSpring’s Principal Investigator in China for Chemotherapy-Induced Neutropenia Delivered Keynote Presentation at 12th Annual Chinese Symposium on Medical Oncology and 7th Annual Meeting of the Chinese Association for Clinical OncologistsPrinter Friendly Version
June 21, 2018BeyondSpring Provides Operational Updates and First-Quarter 2018 Financial ResultsPrinter Friendly Version
June 18, 2018BeyondSpring to Host First-Quarter 2018 Financial Results Conference Call on June 21, 2018Printer Friendly Version
May 31, 2018BeyondSpring to Present at Upcoming ConferencesPrinter Friendly Version
May 30, 2018BeyondSpring Announces $20 Million Registered Direct OfferingPrinter Friendly Version
May 17, 2018BeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the Prevention of Chemotherapy-Induced Neutropenia at 2018 ASCO Annual MeetingPrinter Friendly Version
May 7, 2018BeyondSpring to Present at the Deutsche Bank 43rd Annual Health Care ConferencePrinter Friendly Version
April 25, 2018BeyondSpring to Present Neutropenia Clinical Trial Data on Lead Asset, Plinabulin, at 2018 ASCO Annual MeetingPrinter Friendly Version
April 17, 2018BeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced NeutropeniaPrinter Friendly Version
April 3, 2018BeyondSpring Files Its 2017 Annual Report on Form 20-FPrinter Friendly Version
April 3, 2018BeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial ResultsPrinter Friendly Version
March 27, 2018BeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018Printer Friendly Version
March 27, 2018BeyondSpring Appoints Edward Dongheng Liu as Chief Financial OfficerPrinter Friendly Version
March 19, 2018BeyondSpring Announces Initiation of Phase 3 Clinical Development for Plinabulin for Prevention of Chemotherapy-Induced NeutropeniaPrinter Friendly Version
March 15, 2018BeyondSpring Chief Medical Officer Presents at Three Prominent Industry Conferences in March 2018Printer Friendly Version
February 7, 2018BeyondSpring to Present at Upcoming Investor ConferencesPrinter Friendly Version
February 5, 2018BeyondSpring Summarizes Key Messages from KOL Call regarding Lead Asset Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced NeutropeniaPrinter Friendly Version
January 26, 2018BeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018 ASCO-SITC Clinical Immuno-Oncology SymposiumPrinter Friendly Version
January 17, 2018BeyondSpring to Present Data from Phase 2 Portion of Study 105 Phase 2/3 Trial with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia at 2018 ASCO-SITC Clinical Immuno-Oncology SymposiumPrinter Friendly Version
January 5, 2018BeyondSpring to Present at the 10th Annual Biotech ShowcasePrinter Friendly Version
January 3, 2018BeyondSpring Appoints Life Sciences Veteran Patrick Fabbio to Board of Directors as an Independent MemberPrinter Friendly Version
Print Page Print Page | Email Page Email Page | RSS Feeds RSS Feeds | Email Alerts Email Alerts | IR Contacts Contact IR | Financial Tear Sheet Financial Tear Sheet